These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21741447)

  • 21. Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism.
    Najjar F; Owley T; Mosconi MW; Jacob S; Hur K; Guter SJ; Sweeney JA; Gibbons RD; Cook EH; Bishop JR
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):467-74. PubMed ID: 26262902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between single nucleotide polymorphisms in 5-HT2A signal transduction-related genes and the response efficacy to selective serotonin reuptake inhibitor treatments in Chinese patients with major depressive disorder.
    Li HF; Yu X; Yang K; He CY; Kou SJ; Cao SX; Xie GR
    Genet Test Mol Biomarkers; 2012 Jul; 16(7):667-71. PubMed ID: 22480177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TPH2 polymorphisms may modify clinical picture in treatment-resistant depression.
    Anttila S; Viikki M; Huuhka K; Huuhka M; Huhtala H; Rontu R; Lehtimäki T; Leinonen E
    Neurosci Lett; 2009 Oct; 464(1):43-6. PubMed ID: 19679166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temperament profiles, 5-HT2A genotype, and response to treatment with SSRIs in major depression.
    Andre K; Kampman O; Setälä-Soikkeli E; Viikki M; Poutanen O; Nuolivirta T; Mononen N; Lehtimäki T; Leinonen E; Illi A
    J Neural Transm (Vienna); 2010 Dec; 117(12):1431-4. PubMed ID: 21136126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB.
    Laje G; Cannon DM; Allen AS; Klaver JM; Peck SA; Liu X; Manji HK; Drevets WC; McMahon FJ
    Int J Neuropsychopharmacol; 2010 Jul; 13(6):715-24. PubMed ID: 20047709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic polymorphisms in the serotonergic system and symptom clusters of major depressive disorder.
    Kamata M; Suzuki A; Yoshida K; Takahashi H; Higuchi H; Otani K
    J Affect Disord; 2011 Dec; 135(1-3):374-6. PubMed ID: 21917318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No relationship found between -1438A/G polymorphism of the serotonin 2A receptor gene (rs6311) and major depression susceptibility in a northeastern Thai population.
    Tencomnao T; Thongrakard V; Phuchana W; Sritharathikhun T; Suttirat S
    Genet Mol Res; 2010 Jun; 9(2):1171-6. PubMed ID: 20589614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients.
    Antypa N; Calati R; Souery D; Pellegrini S; Sentissi O; Amital D; Moser U; Montgomery S; Kasper S; Zohar J; De Ronchi D; Mendlewicz J; Serretti A
    J Affect Disord; 2013 Sep; 150(2):649-52. PubMed ID: 23537781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HTR2A gene variation is involved in antidepressant treatment response.
    Lucae S; Ising M; Horstmann S; Baune BT; Arolt V; Müller-Myhsok B; Holsboer F; Domschke K
    Eur Neuropsychopharmacol; 2010 Jan; 20(1):65-8. PubMed ID: 19758789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
    Tomita T; Yasui-Furukori N; Nakagami T; Tsuchimine S; Ishioka M; Kaneda A; Sugawara N; Kaneko S
    PLoS One; 2014; 9(5):e98099. PubMed ID: 24858363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
    Bauer M; Demyttenaere K; El-Khalili N; Thase ME; Papakostas GI; Szamosi J; Earley WR; Eriksson H
    Int Clin Psychopharmacol; 2014 Jan; 29(1):16-25. PubMed ID: 24108148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
    Ball SG; Ferguson MB; Martinez JM; Pangallo BA; Nery ES; Dellva MA; Sparks J; Zhang Q; Liu P; Bangs M; Goldberger C
    J Clin Psychiatry; 2016 May; 77(5):635-42. PubMed ID: 27035159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials.
    Jain R; Chen D; Edwards J; Mathews M
    Curr Med Res Opin; 2014 Feb; 30(2):263-70. PubMed ID: 24127687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study.
    Ozaki N; Otsubo T; Kato M; Higuchi T; Ono H; Kamijima K;
    Psychiatry Clin Neurosci; 2015 Jan; 69(1):34-42. PubMed ID: 24965202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association analysis of SIGMAR1 with major depressive disorder and SSRI response.
    Kishi T; Yoshimura R; Okochi T; Fukuo Y; Kitajima T; Okumura T; Tsunoka T; Kawashima K; Yamanouchi Y; Kinoshita Y; Umene-Nakano W; Naitoh H; Nakamura J; Ozaki N; Iwata N
    Neuropharmacology; 2010 Jun; 58(7):1168-73. PubMed ID: 20178807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?
    Illi A; Poutanen O; Setälä-Soikkeli E; Kampman O; Viikki M; Huhtala H; Mononen N; Haraldsson S; Koivisto PA; Leinonen E; Lehtimäki T
    Eur Arch Psychiatry Clin Neurosci; 2011 Mar; 261(2):95-102. PubMed ID: 20640435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial.
    Brunoni AR; Carracedo A; Amigo OM; Pellicer AL; Talib L; Carvalho AF; Lotufo PA; Benseñor IM; Gattaz W; Cappi C
    Braz J Psychiatry; 2020 Apr; 42(2):128-135. PubMed ID: 31721892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Converging translational evidence for the involvement of the serotonin 2A receptor gene in major depressive disorder.
    Petit AC; Quesseveur G; Gressier F; Colle R; David DJ; Gardier AM; Ferreri F; Lépine JP; Falissard B; Verstuyft C; Guiard BP; Corruble E
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():76-82. PubMed ID: 24801750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.